Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer

  • End date
    Sep 1, 2024
  • participants needed
  • sponsor
    Health Science Center of Xi'an Jiaotong University
Updated on 7 October 2021
cancer chemotherapy
fallopian tube
peritoneal cancer
cancer of the ovary


In this study, The researchers sought to explore the efficacy and safety of involving field radiotherapy in the oligo-metastatic/recurrent/refractory ovarian cancer patients among different groups which include drug therapy alone, radiotherapy alone, and drug therapy plus radiotherapy by inviting clinical multi-center participation.


The recurrent or refractory ovarian cancer tends to recur repeatedly at increasingly short intervals, making treatment more and more difficult.Patients often have limited physical capacity to undergo repeated systematic treatment. Currently, NCCN national comprehensive cancer network guidelines recommend palliative radiotherapy in patients with local recurrence of ovarian cancer. With the progress of IMRT intensity modulated radiation therapy , SBRT ( stereotactic body radiation therapy ) and other radiotherapy technologies, better local tumor control rate can also be achieved, while minimizing the damage to surrounding normal tissues. In this study, the patients will be divided into groups according to their wishes: group A (drug therapy alone), group B (radiotherapy alone), and group C (radiotherapy plus drug therapy).The researchers sought to explore the the efficacy and safety of involving field radiotherapy in the oligo-metastatic/recurrent/refractory ovarian cancer patients in different groups after treatment by inviting multiple centers to participate in the study.

Condition ovarian tumors, Ovarian Cancer, cancer of the ovary, Ovarian Function, Cancer, Ovarian Stromal, Recurrent Ovarian Cancer, ovarian carcinomas, cancer, ovarian, Ovarian disorder, cancer ovarian
Treatment chemotherapy, targeted therapeutics, immunotherapy, IFRT, IMRT or SBRT
Clinical Study IdentifierNCT05059782
SponsorHealth Science Center of Xi'an Jiaotong University
Last Modified on7 October 2021


Yes No Not Sure

Inclusion Criteria

Age 18
Evidence of histological diagnosis of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer)
Pathology or imaging suggested recurrence, with measurable lesions, and the number of lesions 3
No serious hematopoietic dysfunction, abnormal heart, lung, liver, kidney and immune deficiency
Cooperative Oncology Group-Status (ECOG Status) score 0-2
Expected survival 3 months
Feasible abdomen and pelvic cavity MRI/CT
Good compliance, signed informed consent voluntarily

Exclusion Criteria

Previous radiotherapy at the target lesion site
History of active inflammatory bowel disease or severe stomach and duodenal ulcers
Human immunodeficiency virus (HIV) infected persons
active hepatitis b (HBVDNA quantitative test results exceed the lower limit), or HCV infection (HCVRNA quantitative test results exceed the lower limit)
suffering from serious underlying diseases, including but not limited to active infections requiring systemic medication
patients with a history of other malignant tumors (except cured basal cell carcinoma of the skin)
neurological or mental disorders that affect cognitive ability
Patients whose lesions have been evaluated by the investigator and cannot be treated with external irradiation or endovascular radiation therapy
those who cannot follow up regularly as prescribed by the doctor
Other reasons not suitable for participating in this study as judged by the researcher
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note